MedWatch

Hovione enters partnership with Zerion Pharma

A partnership between global contract manufacturer Hovione and Zerion Pharma is a validation of the company’s technology that can increase the solubility of oral drugs, says the latter company’s CEO, Ole Wiborg, who is pleased about acquiring a global partner committed to delivering a number of projects.

Ole Wiborg, CEO of Zerion Pharma | Photo: Zerion Pharma/PR

Zerion Pharma, which is focused on improving existing drugs’ effect by increasing the solubility of oral medications, has entered a strategic partnership with Hovione, which is a global contract development and manufacturing organization (CDMO) dealing with generic drugs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs